Jacobs Levy Equity Management’s Axsome Therapeutics AXSM Stock Holding History

Jacobs Levy Equity Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.82M	Buy	+11,533	New	+$2.5M	0.01%	531
2020 Q1	–	Sell	-42,438	Closed	-$4.39M	–	1006
2019 Q4	$4.39M	Sell	42,438 -31,827	-43%	-$1.29M	0.04%	396
2019 Q3	$1.5M	Hold	74,265	–	–	0.02%	561
2019 Q2	$1.91M	Hold	74,265	–	–	0.03%	531
2019 Q1	$1.06M	Sell	74,265 -9,900	-12%	-$91.9K	0.02%	646
2018 Q4	$237K	Buy	84,165 +20,800	+33%	+$68.4K	﹤0.01%	848
2018 Q3	$219K	Buy	+63,365	New	+$188K	﹤0.01%	915

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management's AXSM Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 11,533 shares worth $2.82M. The stake represents 0.01% of the portfolio and ranks #531 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in AXSM as recently as Q4 2019.

Jacobs Levy Equity Management first reported a position in AXSM in Q3 2018 and has held it in 7 quarters since. The position peaked at $4.39M in Q4 2019. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Jacobs Levy Equity Management held 11,533 shares of Axsome Therapeutics worth $2.82M as of Q2 2026.
Axsome Therapeutics was a new Jacobs Levy Equity Management position in Q2 2026.
Axsome Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #531 holding.
Jacobs Levy Equity Management first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 7 quarters since.
Jacobs Levy Equity Management's Axsome Therapeutics position peaked at $4.39M in Q4 2019.
505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.